Navigation Links
Intarcia Announces Expanded Appointment for Kurt Graves as Chairman, President and Chief Executive Officer
Date:4/2/2012

for our shareholders.  Nowhere is this potential more obvious than in type 2 diabetes, where we have what we believe to be a once-in-a-lifetime opportunity to help the hundreds of millions of patients worldwide challenged by this devastating disease.  I am also looking forward to building on our innovative drug delivery platforms and our state-of-the-art manufacturing facility in California while we open our new headquarters in the Boston area, a region with deep resources and unparalleled innovation networks to support a growing life science company."

About ITCA 650
ITCA 650 (DUROS® continuous subcutaneous delivery of exenatide) is being developed for the treatment of type 2 diabetes. The investigational therapy comprises Intarcia's DUROS delivery device, a matchstick-size, miniature osmotic pump that is inserted subcutaneously to provide continuous and consistent drug therapy, and the company's proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for extended periods of time. The combined technologies can deliver up to a full year of injection-free therapy from a single ITCA 650 placement.

Data from Intarcia's ITCA 650 Phase 2 program have demonstrated significant and sustained reductions in HbA1c and body weight over 48 weeks of treatment with a marked reduction in the GI adverse events typically associated with the self-injection products in this class. ITCA 650 is an investigational new therapy and is not currently approved by any regulatory authority. Exenatide, the active agent in ITCA 650, is a glucagon-like peptide-1 (GLP-1) receptor agonist currently marketed globally as a twice-daily and once-weekly self-injection therapy for type 2 diabetes. Upon approval, ITCA 650 would represent the first injection-free GLP-1 therapy that can deliver up to a full year of treatment from a single placement. Intarcia's robust intellectual pro
'/>"/>

SOURCE Intarcia Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research
2. Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions
3. Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions
4. Intarcia Therapeutics, Inc. Commences Enrollment of ITCA 650 Phase 2 Study in Type 2 Diabetes
5. Intarcia Therapeutics, Inc. Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabetes Conference
6. Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting
7. Intarcia Therapeutics Executive Chairman, Kurt Graves to Present at Lazard Capital Markets 7th Annual Healthcare Conference
8. Intarcia Presents Positive Phase 2 48-week Results From ITCA 650 Study at the American Diabetes Association 71st Scientific Sessions
9. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
10. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
11. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Md. , Dec. 24, 2014  United ... today that Medtronic, Inc. (NYSE: MDT ... the U.S. Food and Drug Administration (FDA) for ... implantable drug infusion system (including a newly developed ... (treprostinil) Injection delivered intravenously to patients with ...
(Date:12/24/2014)... and NEW YORK , ... PTBI, PTBIW), a biopharmaceutical company advancing patient care in ... offering of 3,500,000 shares of common stock, and warrants ... common stock, at an offering price of $4.00 per ... per share exercise price of $5.00, are exercisable immediately, ...
(Date:12/24/2014)... 24, 2014  Vermillion, Inc. (Nasdaq:   VRML), ... announced today that the Company closed its previously ... Management, Jack W. Schuler , Birchview Fund ... $10.5 million, before offering expenses.  The proceeds will ... purposes. Under the terms of the ...
(Date:12/24/2014)... 24, 2014   BioLife Solutions , Inc. (NASDAQ: ... marketer of proprietary clinical grade hypothermic storage ... thermal shipping products for cells and tissues  ("BioLife" ... its 2015 Annual Meeting of Stockholders on May 4, ... date for the Annual Meeting represents a change of ...
Breaking Biology Technology:United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3BioLife Solutions Sets Date for Annual Meeting of Stockholders 2
... Silicon Graphics, Inc . has received interim approval from ... million financing facility to fund day-to-day business operations during ... hearing in which the U.S. Bankruptcy Court for the ... first-day motions to protect employees, suppliers, and customers. The ...
... year after Chippewa Valley Technical College pioneered ... approved a $1.5 million grant to help build the ... will cover part of the cost of construction for ... estimated 650 jobs and generate $30 million in private ...
... - RedPrairie Corp. , the Waukesha-based ... of supply-chain solutions during a recent user conference. , ... logistics industry summit, RedPrairie unveiled its E2e suite of ... addresses the consumer-driven supply chain challenges faced by customers. ...
Cached Biology Technology:SGI receives court approval for bankruptcy motions 2
(Date:12/24/2014)... 2014  Since its launch in December 2014, the ... to eliminate the pain of trying to remember their ... their own biometrics fused to their smartphones. To assist ... Hoyos Labs , the company that created 1U ... is offering the app for free. 1U ...
(Date:12/22/2014)... -- NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) ... on the growing mobile commerce market, announces it has ... Robbins for the 2015 International CES debut of ... Apollo Robbins will be at the NXT-ID booth ... of his famous theft techniques to visiting media and ...
(Date:12/22/2014)... 22, 2014 Research and Markets ... addition of the "The Global Watermarking ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... overview of the global digital media watermarking ... and monitor piracy by securely and invisibly ...
Breaking Biology News(10 mins):1U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 4The Global Watermarking and Fingerprinting Markets 2
... RNA component units called ribonucleotides become embedded in genomic ... organism, they can cause problems for cells. It is ... DNA double helix, resulting in genomic instability and altered ... fate of these ribonucleotides. A new study provides ...
... 3, 2011--A "team" of fast-moving, bone marrow stem cells from ... first World Cell Race, finishing first with a cellular speed ... minute) in results announced today at the 51st Annual Meeting ... The mesenchymal bone marrow stem cells grown at the National ...
... In a paper published in the December 2011 issue ... of scientists at the University of Illinois, Urbana-Champaign led ... and host inflammatory factors modulate sulfomucin production in a ... Sulfomucins, one of two primary types of ...
Cached Biology News:Study identifies mechanisms cells use to remove bits of RNA from DNA strands 2Microscopic cells race to victory in first World Cell Race at ASCB meeting 2Microscopic cells race to victory in first World Cell Race at ASCB meeting 3Inflammatory cues modulate goblet cell products important for intestinal barrier function 2Inflammatory cues modulate goblet cell products important for intestinal barrier function 3
Mouse monoclonal antibody raised against a partial recombinant VRK2. NCBI Entrez Gene ID = VRK2...
Mouse monoclonal antibody raised against a full length recombinant PPIL2. NCBI Entrez Gene ID = PPIL2...
Mouse monoclonal antibody raised against a partial recombinant L3MBTL2. NCBI Entrez Gene ID = L3MBTL2...
Mouse monoclonal antibody raised against a partial recombinant ALAS2. NCBI Entrez Gene ID = ALAS2...
Biology Products: